Company Reports Q2 Revenue of $373.9M, Exceeding Expectations
Reports Q2 revenue $373.9M, consensus $355.64M. "This was a strong quarter for us, and I'm really proud of how our teams are executing around the world," stated Jack Bendheim, President and Chief Executive Officer. "We're seeing faster than expected uptake of our newly integrated MFA portfolio, which is already giving our results a real lift. At the same time, our nutritional specialty and vaccine offerings continue to deliver strong, sustained growth across key markets. With this momentum and the progress we're making across the business, we feel confident raising our full year guidance. Even with some of the challenges in the global environment, our people continue to show resilience and stay focused on delivering for our customers. With the strategy we have in place and the dedication of our teams, I feel very good about where we're headed."
